臺灣博碩士論文加值系統

本研究為描述萘并[2,3-b]呋喃-4,9-二酮衍生物之合成以及抗增生活性評估。我們合成了一系列在N-1，C-2，C-4位置上有取代的衍生物，並研究此衍生物抗增生活性結構活性和衍生物之取代機種類與取代基位置之關聯性。最初的結果顯示，(E)-1-cyclopropyl-4,9-dioxo-4,9-dihydro-naphtho[2,3-d] imidazole-2-carbaldehyde O-2-(piperidin-1-yl)ethyl oxime (20), (Z)-N-(4-(1-ethyl-2-methyl-9-oxo-naphtho[2,3-d]imidazol-ylideneamino-phenyl)acetamide (21d), (Z)-4-(1-cyclopropyl-2-methyl-9-oxo-naphtho[2,3-d]imidazol- ylideneamino)-N-(2-(diethylamino)ethyl)benzamide (21e)與及1-(3-(Dimethylamino)propyl)-2-(furan-2-yl)-1H-naphtho[2,3-d]imidazole-4,9- dione (25e)，並展現出對於A549細胞株具有選擇性抑制活性，其GI50值為6.40，6.93和6.48μM。(25e)對CE81T細胞株的GI50值為4.78μM。

This thesis describes synthesis and antiproliferative evaluation of naphtho[2,3-b]furan-4,9-dione derivatives. A number of substituents have been introduced on the N-1, C-2, or C-4 position to investigate the antiproliferative structure activity relationship with respect to the kind of substituents and the position of substitution. Preliminary results indicated that (E)-1-cyclopropyl-4,9-dioxo-4,9-dihydro-naphtho[2,3-d]imidazole- 2-carbaldehyde O-2-(piperidin-1-yl)ethyl oxime (20), (Z)-N-(4-(1-ethyl-2-methyl-9-oxo-naphtho[2,3-d]imidazol-ylideneamino- phenyl)acetamide (21d), and (Z)-4-(1-cyclopropyl-2-methyl-9-oxo- naphtho[2,3-d]imidazol-ylideneamino)-N-(2-(diethylamino)ethyl)benzamide (21e) , 1-(3-(Dimethylamino)propyl)-2-(furan-2-yl)-1H-naphtho[2,3-d]imidazole -4,9- dione (25e) exhibited selective inhibitory activity against the growth of A549 cancer cell line with GI50 value of 6.40, 6.93, and 6.48 ?嵱 respectively. Compound (25e) of the CE81T cell lines GI50 value is 4.78μM

中文摘要………………………………………………………1
英文摘要………………………………………………………2
壹、 緒論………………………………………………………3
貳、 研究動機……………………………………………… 10
參、 研究方法……………………………………………… 20
肆、 合成方法與及結果與討論…………………………… 24
一：萘并[2,3-d]咪唑-4,9-二酮衍生物18a-q之合成…....................……24
二：萘并[2,3-d]咪唑-4,9-二酮衍生物19a-之合成……...........…………25
三：萘并[2,3-d]咪唑-4,9-二酮衍生物20合成..........................................25
四：萘并[2,3-d]咪唑-4,9-二酮衍生物21a-e之合成.................................26
五：萘并[2,3-d]咪唑-4,9-二酮衍生物22a-b之合成................................28
伍、結果與討論………………………………………………29
陸、結論………………………………………………………34
柒、實驗部份…………………………………………………36
捌、參考文獻…………………………………………………76

1.Hanahan, D.; Weinberg, R. A. The hallmarks of cancer. Cell. 2000, 100, 57-70
2.Wani, M. C.; Taylor, H. L.; Monroe E. Wall; Coggon, P.; McPhail A. T. Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus breoifolia. J. Am. Chem. Soc. 1971, 93 , 2325–2327.
3.Zhang, N.; Ayral-Kaloustian, S.; Nguyen, T.; Afragola, J.; Hernandez, R.; Lucas, J.; Gibbons, J.; Beyer, C. Synthesis and SAR of [1,2,4]triazolo[1,5-a] pyrimidines, a class of anticancer agents with a unique mechanism of tubulin inhibition. J. Med. Chem. 2007, 50, 319–327.
4.Patterson, D. M.; Rustin, G. J. S. Vascular damaging agents. Clinical Oncology 2007, 19, 443-456.
5.Johnson I. S.; Armstrong J. G.; Gorman, M.; Burnett, J. P. The vinca alkaloids: a new class of oncolytic agents. Cancer Res. 1967, 23, 1390–427.
6.Yang, S. P.; Lee, C. K. The historical review of camptothecin and its derivatives. The Chinese Chemical Society 2009, 67, 45-60.
7.Wall, M. E.; Wani, M. C.; Cook, C. E.; Palmer, K. H. Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from camptotheca acuminate. J. Am. Chem. Soc. 1966, 88, 3888-3890.
8.Abou-Alfa, G. K.; Letourneau, R.; Harker, G.; Modiano, M.; Hurwitz, H.; Tchekmedyian, N. S.; Feit, K.; Ackerman, J.; Jager, R. L. D.; Eckhardt, S. G.; O’Reilly E. M. Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J. Clin. Oncol. 2006, 24,4441-4447.
9.Hartwell, J. L.; Schrecker, A. W. Components of podophyllin. V. The constitution of podophyllotoxin. J. Am. Chem. Soc. 1951, 73, 2909-2916.
10.Tan, C.; Tasaka, H.; Yu, K. P.; Murphy, M. L.; Karnofsky, D. A. Daunomycin, an antitumor antibiotic, in the treatment of neoplastic disease. Clinical evaluation with special reference to childhood leukemia. Cancer 1967, 20, 333–353.
11.Murdock, K. C.; Child, R. G.; Fabio, P. F.; Angier, R. B.; Wallace, R. E.; Durr, F. E.; Citarella, R. V. Antitumor agents. 1.1,4-Bis[(aminoalkyl)amino]-9,10 -anthracenediones. J. Med. Chem. 1979, 22, 1024-1030.
12.John, L.; Nitiss, Targeting DNA topoisomerase II in cancer chemotherapy. Nature Reviews Cancer 2009, 9, 338-350.
13.Brian, B. H.; Michael, E. A.; Norman, B.; Tayeb, K.; William, P. A.; Jack, C. Y. The catalytic DNA topoisomerase II inhibitor Dexrazoxane (ICRF-187) induces differentiation and apoptosis in human leukemia K562 cells. Mol. Pharmacol. 2001, 59, 453-61.
14.Moore, M.H.; Hunter, W.N.; d''Estaintot, B.L.; Kennard, O. DNA-drug interactions. The crystal structure of d(CGATCG) complexed with Daunomycin. J. Mol. Biol. 1989, 206, 693-705.
15.Pindur, U.; Haber, M.; Sattler, S. Antitumor active drugs as lntercalators of deoxyribonucleic acid. J. Chem. Educ. 1993, 7, 263-269.
16.Rao, M. M.; Kingston, D. G. Plant A-nticancer agents. xii.1 isolation and structure elucidation of new cytotoxic quinones from Tabebuia cassinoides. J. Nat. Prod. 1982, 45, 600-604.

17.Gunatilaka, A. A. L.; Kingston, D. G. I.; Johnson, R. K. Mechanism-based isolation and structures of some anticancer active natural products. Pure & Appl. Chem. 1994, 66, 2219-2222.
18.Huang, L. J.; Kuo S. C.; Pemg, C. Y.; Chao, Y. H.; Wu, T. S.; McPhail, A. T., Mauger, A.; Cheng, H. H.; Lee K. H. Synthsis and cytotoxicity of acetyl-4H, 9H-Naphtho[2,3-b]thiophene-4,9-diones. Bioorg. Med. Chem. Lett. 1998, 8, 2763-2768.